Register

Rheumatology

NEJM Journal Club   

Questions discussed in this category

How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?
Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk.  However, RA itself is cons...
2 Answers available
What role do you see for JAK inhibitors in RA treatment strategies given the data we now have regarding CV and cancer outcomes?
For example, would it be appropriate to consider JAK inhibitor therapy as preferable to TNF-alpha inhibitor in patients with heart failure with reduce...
4 Answers available
Would you recommend that a patient with stable coronary artery disease and well-controlled RA on a JAK inhibitor continue on their current therapy?
2 Answers available
Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?
2 Answers available
How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?
2 Answers available
Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?
ADVOCATE trial
1 Answer available
How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?
In the ADVOCATE trial, patients were not re-dosed with rituximab.
1 Answer available
Are there particular subsets of AAV patients in which avacopan is more effective?
E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...
1 Answer available


Papers discussed in this category

N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Ann Rheum Dis, 2016 Oct 03
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
N Engl J Med,
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Arthritis Rheumatol, 2021 Mar 24
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.

Related Topics in Rheumatology

Copyright © 2025 theMednet
All Rights Reserved.